Orbimed advisors sells $16.97 million in disc medicine shares

OrbiMed Advisors LLC, a director at Disc Medicine, Inc. (NASDAQ:IRON), has reported significant sales of the company’s common stock. According to a recent SEC filing, OrbiMed Advisors sold shares totaling approximately $16.97 million over several transactions. The sale represents a notable movement for the biotechnology company, which currently maintains a market capitalization of $1.86 billion. InvestingPro analysis indicates the stock is currently fairly valued based on its proprietary Fair Value model. The sales occurred between March 10 and March 12, 2025, with share prices ranging from $54.01 to $55.05, near the middle of its 52-week range of $25.60 to $68.86. Following these transactions, OrbiMed Advisors retains a substantial holding in Disc Medicine. Notably, InvestingPro data shows strong analyst interest in the stock, with a consensus target price ranging from $75 to $118. Get access to 8 additional exclusive ProTips and comprehensive analysis through the Pro Research Report, available for over 1,400 US stocks.

In other recent news, Disc Medicine has been the focus of several analyst updates and developments. Cantor Fitzgerald maintained its Overweight rating for Disc Medicine, keeping a price target of $99, after adjusting its financial model to reflect the latest share count and operating expenses following a recent public offering. Scotiabank (TSX:BNS) raised its price target for Disc Medicine to $75 from $73, citing the company’s plans for a New Drug Application submission for bitopertin in 2025 and the commencement of a phase 3 trial. Meanwhile, TD Cowen initiated coverage on Disc Medicine with a Buy rating, highlighting the potential market opportunities for the company’s drugs, particularly bitopertin and 0974, in treating erythropoietic protoporphyria and myelofibrosis anemia, respectively.

Stifel also adjusted its price target for Disc Medicine, increasing it to $94 from $90, while maintaining a Buy rating. This adjustment follows Disc Medicine’s authorization to submit an NDA for bitopertin, with an estimated 85% chance of approval. Stifel’s analysis suggests a commercial launch for bitopertin in 2026 and anticipates further insights from upcoming data on myelofibrosis and chronic kidney disease. These updates reflect a range of analyst perspectives on Disc Medicine’s financial health and strategic direction, indicating a generally positive outlook from the investment community.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.